Study With a Topical Gel to Treat Common Warts in Adults

NCT00117923 — Phase 2, Completed, 88 participants, Graceway Pharmaceuticals, LLC

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 5 Times Per Week for 4 Weeks for the Treatment of Common Warts in Adults

Registry	NCT00117923
Status	Completed
Phase	Phase 2
Study type	Interventional; non randomized, single group, masking: single, treatment
Enrollment	88
Sponsor	Graceway Pharmaceuticals, LLC (Industry)
Conditions	Warts
Interventions	Resiquimod (Drug)
Dates	start 2004-08-01, first posted 2005-07-11, last updated 2007-02-19
Locations	1 site in United States

-Summary

The primary purpose of this study is to evaluate the effectiveness in adults of four different strengths of resiquimod gel applied to common wart(s) five times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Expand all sections · Collapse all

+Arms and interventions

Resiquimod (Drug)

+Outcome measures

Primary outcomes

Clearance of treated wart(s)

Secondary outcomes

Partial clearance of treated wart(s)
Wart recurrence

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Diagnosis of common warts
* Two forms of birth control

Exclusion Criteria:

* Pregnant or breast feeding
* Other types of warts, ie. plantar
* Currently participating in another clinical study
* Chronic viral hepatitis B or C

+Locations (1)

Facility	City	Country	Status
Oregon Medical Research Center	Portland, Oregon	United States